Literature DB >> 2987558

AIDS serology testing in low- and high-risk groups.

J R Carlson, M L Bryant, S H Hinrichs, J K Yamamoto, N B Levy, J Yee, J Higgins, A M Levine, P Holland, M B Gardner.   

Abstract

The performance characteristics of the acquired immunodeficiency syndrome (AIDS)-retrovirus serological tests including enzyme-linked immunosorbent assay (ELISA), Western blot, and immunofluorescence assay were defined in a clinical laboratory setting by testing 1,257 serum specimens from low- and high-risk groups for AIDS. The three prototype AIDS retroviruses (lymphadenopathy-associated virus, human T-lymphotropic virus III, and AIDS-associated retrovirus) were equally suitable as target antigen for these assays. Sera from six of 74 laboratory and health care personnel and 91 of 1,014 unselected blood donors were falsely positive by ELISA (positive to negative ratio [P/N], greater than or equal to 2) based on the lack of Western blot confirmation. Only two true-positives (two [0.2%] of 1,014 blood donors) were detected in these low-risk groups. In contrast, 106 of 108 specimens with ELISA P/N ratios of 2 or greater from the high-risk groups including asymptomatic homosexual men, hemophiliacs, AIDS-related complex patients, and AIDS patients were positive by Western blot and immunofluorescence assay. Four false-negative ELISA results based on positive immunofluorescence assay and Western blot were found in the AIDS patient group. Ten of 69 AIDS patients were negative by all three serological tests. The consequence of maintaining high sensitivity for the ELISA (P/N ratio, greater than or equal to 2) as a screening test was a loss of specificity. The number of false-positive results necessitated the use of a confirmation test with greater specificity.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2987558

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  25 in total

1.  Evaluation of a human immunodeficiency virus test algorithm utilizing a recombinant protein enzyme immunoassay.

Authors:  D G Lepine; P W Neumann; S L Frenette; M V O'Shaughnessy
Journal:  J Clin Microbiol       Date:  1990-06       Impact factor: 5.948

Review 2.  The natural history of human T lymphotropic virus-III infection: the cause of AIDS.

Authors:  M Melbye
Journal:  Br Med J (Clin Res Ed)       Date:  1986-01-04

3.  Sensitivity and specificity of pooled versus individual sera in a human immunodeficiency virus antibody prevalence study.

Authors:  B Cahoon-Young; A Chandler; T Livermore; J Gaudino; R Benjamin
Journal:  J Clin Microbiol       Date:  1989-08       Impact factor: 5.948

4.  Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro.

Authors:  J F Krowka; D P Stites; S Jain; K S Steimer; C George-Nascimento; A Gyenes; P J Barr; H Hollander; A R Moss; J M Homsy
Journal:  J Clin Invest       Date:  1989-04       Impact factor: 14.808

5.  HIV seropositivity and IVDUs: ethnic/gender comparisons.

Authors:  D K Lewis; J K Watters
Journal:  Am J Public Health       Date:  1988-11       Impact factor: 9.308

6.  Comparison of enzyme immunoassays and an immunofluorescence test for detection of antibody to human immunodeficiency virus in African sera.

Authors:  G Vercauteren; G van der Groen; P Piot
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

7.  Dot immunobinding assay compared with enzyme-linked immunosorbent assay for rapid and specific detection of retrovirus antibody induced by human or simian acquired immunodeficiency syndrome.

Authors:  R L Heberling; S S Kalter; P A Marx; J K Lowry; A R Rodriguez
Journal:  J Clin Microbiol       Date:  1988-04       Impact factor: 5.948

8.  Utility of quantitative enzyme immunoassay reactivity for predicting human immunodeficiency virus seropositivity in low- and high-prevalence populations.

Authors:  X Hou; P L Breese; J M Douglas
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

9.  Advantages of a human immunodeficiency virus type 1 (HIV-1) persistently infected HeLa T4+ cell line for HIV-1 indirect immunofluorescence serology.

Authors:  B Forghani; J W Hurst; C S Chan
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

10.  Comparison of indirect immunofluorescence and Western blot for detection of anti-human immunodeficiency virus antibodies.

Authors:  J R Carlson; J Yee; S H Hinrichs; M L Bryant; M B Gardner; N C Pedersen
Journal:  J Clin Microbiol       Date:  1987-03       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.